Status:
COMPLETED
Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Severe Postpartum Haemorrhage
Eligibility:
FEMALE
Brief Summary
This non-interventional study will compare the clinical outcomes in women with an event of severe postpartum haemorrhage treated with NovoSeven® to clinical outcomes in women with an event of severe p...
Eligibility Criteria
Inclusion
- Females
- sPPH, defined as continuous bleeding of more than 1500 mL within 24 hours after delivery
- Inclusion in one of the four cohorts (historical cohort 1, historical cohort 2, study cohort and new cohort)
Exclusion
- There are no exclusion criteria
Key Trial Info
Start Date :
June 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2021
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT04444856
Start Date
June 29 2020
End Date
January 13 2021
Last Update
January 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Bern, Switzerland, CH-3010